Fundraising FoxGEMMABio
Philadelphia, US · 5 known investors
Find your way into GEMMABio
GEMMABio is a biotechnology company developing gene therapies for rare diseases using next-generation AAV technology, with programs spanning motor neuron disorders and skeletal and cardiomyopathies. It focuses on making treatments accessible to patients globally, with an emphasis on the rare disease community.
Founders & leadership
+recolor.png)
Investors · 5
How we know: IKJ Capital's portfolio page · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements$34M disclosed across 1 of 2 rounds · 2024–2025
- Undisclosed amountseed roundJan 2025
Bioluminescence Ventures (lead), Double Point Ventures (lead), Earlybird Venture Capital (lead), Savanne Life Sciences
Source ↗ - $34Mseed funding roundDec 2024 · 3 sources
Bioluminescence Ventures (lead), Double Point Ventures (lead), Earlybird Venture Capital (lead), Savanne Life Sciences
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Frequently asked questions
- What does GEMMABio do?
- GEMMABio is a biotechnology company developing gene therapies for rare diseases using next-generation AAV technology, with programs spanning motor neuron disorders and skeletal and cardiomyopathies. It focuses on making treatments accessible to patients globally, with an emphasis on the rare disease community.
- Who founded GEMMABio?
- GEMMABio was founded by James M. Wilson.
- Who are GEMMABio's investors?
- GEMMABio's investors include IKJ Capital, Bioluminescence Ventures, Earlybird Venture Capital.
- How much funding has GEMMABio raised?
- GEMMABio has disclosed $34M raised across 1 of its 2 known rounds.
- Where is GEMMABio headquartered?
- GEMMABio is headquartered in Philadelphia, US.